Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-046897
Filing Date
2022-08-11
Accepted
2022-08-11 16:26:29
Documents
47
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0622_citiuspharma.htm   iXBRL 10-Q 621403
2 CERTIFICATION f10q0622ex31-1_citius.htm EX-31.1 10386
3 CERTIFICATION f10q0622ex31-2_citius.htm EX-31.2 10509
4 CERTIFICATION f10q0622ex32-1_citius.htm EX-32.1 5669
  Complete submission text file 0001213900-22-046897.txt   3560421

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctxr-20220630.xsd EX-101.SCH 49672
6 XBRL CALCULATION FILE ctxr-20220630_cal.xml EX-101.CAL 29202
7 XBRL DEFINITION FILE ctxr-20220630_def.xml EX-101.DEF 171154
8 XBRL LABEL FILE ctxr-20220630_lab.xml EX-101.LAB 391237
9 XBRL PRESENTATION FILE ctxr-20220630_pre.xml EX-101.PRE 181625
41 EXTRACTED XBRL INSTANCE DOCUMENT f10q0622_citiuspharma_htm.xml XML 354439
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-38174 | Film No.: 221156271
SIC: 2834 Pharmaceutical Preparations